What medications are referred to as 'California rocket fuel' for treating depression, specifically which Selective Serotonin Reuptake Inhibitor (SSRI) and norepinephrine-dopamine reuptake inhibitor are used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

California Rocket Fuel: Mirtazapine Plus Venlafaxine

"California Rocket Fuel" refers to the combination of mirtazapine (a noradrenergic and specific serotonergic antidepressant, NaSSA) and venlafaxine (a serotonin-norepinephrine reuptake inhibitor, SNRI), used for treatment-resistant depression. 1

The Two Medications

  • Venlafaxine: An SNRI that inhibits reuptake of both serotonin and norepinephrine 2
  • Mirtazapine: A NaSSA (not an SSRI) that enhances noradrenergic and serotonergic neurotransmission through alpha-2 antagonism 1

Rationale for This Combination

The combination targets multiple neurotransmitter systems simultaneously, which theoretically provides enhanced antidepressant efficacy compared to single-agent therapy. 1

Dual-acting antidepressants (those affecting both norepinephrine and serotonin) have demonstrated superiority over SSRIs in severe depression, with tertiary amine tricyclics like amitriptyline and clomipramine showing particular advantage in hospitalized or severely depressed patients. 3

SNRIs like venlafaxine provide marginally superior remission rates compared to SSRIs (49% vs. 42%) in major depressive disorder, with additional benefits for patients with comorbid pain disorders. 3

Clinical Application

This combination is specifically indicated for treatment-resistant depression—patients who have failed to respond to initial adequate trials of standard antidepressants. 1

Preclinical studies demonstrate that sub-effective doses of mirtazapine (5 mg/kg) combined with venlafaxine (7.5 mg/kg) reduced immobility in forced swim tests without affecting motor activity or causing sexual dysfunction. 1

Important Caveats

Risk of hypomanic switching: This combination carries significant risk of inducing profound alterations in mental state, including drug-induced hypomania, and should be reserved for carefully selected patients with close monitoring. 4

The combination should only be used after failure of first-line treatments, as second-generation antidepressants (SSRIs and SNRIs) are considered equally effective for treatment-naïve patients. 3

References

Research

SNRIs: mechanism of action and clinical features.

Expert review of neurotherapeutics, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.